NetraMark’s AI could cut drug trial costs in half
NetraMark and Worldwide Clinical Trials have partnered to deploy NetraMark’s NetraAI platform, enhancing clinical trial design through AI-powered precision analytics. The collaboration aims to optimize patient-centric clinical trials by identifying hidden subpopulations within complex datasets.
Worldwide Clinical Trials, recognized for its three decades of clinical execution and 11 CRO Leadership Awards, will integrate NetraMark’s NetraAI platform. This platform is designed to improve clinical trial efficiency and provide regulatory-aligned insights from complex datasets.
Initially, NetraMark’s AI technology will be used in Phase 2 (neuroscience and oncology) and select Phase 3 clinical trials conducted by Worldwide. The companies plan to broaden its availability to all Worldwide sponsors across all therapeutic areas and trial phases.
NetraAI will be incorporated into Worldwide’s offerings as a dedicated solution to streamline workflow for sponsors. Worldwide aims to accelerate development timelines, refine patient stratification, reduce placebo response variability, and enhance overall trial power through this integration.
IBM’s AI elevates your Masters Tournament experience
“With this agreement, our goal is to unlock the full potential of AI to reshape the future of clinical development,” said George Achilleos, CEO of NetraMark. Dave Bowser, Chief Operating Officer at Worldwide Clinical Trials, added, “By integrating NetraMark’s technology into our clinical trial design, we can identify the patients most likely to drive positive trial outcomes, leading to fewer required patients per trial, reduced timelines, lower costs, and ultimately increase success rates for our sponsors.”
Worldwide Clinical Trials is a global contract research organization (CRO) providing customized solutions for biotechnology and pharmaceutical companies. Their services include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies, spanning over 60 countries with more than 3,500 team members.
NetraAI uses focus mechanisms to separate small datasets into explainable and unexplainable subsets; this contrasts with other AI methods. The platform derives insights and hypotheses from explainable subsets, potentially increasing a clinical trial’s chance of success.
NetraMark focuses on developing Generative AI (Gen AI)/Machine Learning (ML) solutions for the pharmaceutical industry. Its algorithm parses patient data sets into strongly related subsets, enabling accurate disease segmentation and patient classification for drug sensitivity and treatment efficacy.